245 related articles for article (PubMed ID: 17403057)
1. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Larsen R; Ryder LP; Svejgaard A; Gniadecki R
Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
[TBL] [Abstract][Full Text] [Related]
2. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
[TBL] [Abstract][Full Text] [Related]
3. The effect of alefacept on T-cell subsets and cells expressing NK receptors in lesional psoriatic skin: the effects of monotherapy and combination treatment with calcipotriol.
Vissers WH; van Duijnhoven M; van Erp PE; de Jong EM; van de Kerkhof PC
J Dermatolog Treat; 2008; 19(6):344-50. PubMed ID: 19016104
[TBL] [Abstract][Full Text] [Related]
4. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN; Krueger GG;
N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
[TBL] [Abstract][Full Text] [Related]
6. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
Ortonne JP; Lebwohl M; Em Griffiths C;
Eur J Dermatol; 2003; 13(2):117-23. PubMed ID: 12695125
[TBL] [Abstract][Full Text] [Related]
7. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Chamian F; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG; Lowes MA
J Transl Med; 2007 Jun; 5():27. PubMed ID: 17555598
[TBL] [Abstract][Full Text] [Related]
8. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
[TBL] [Abstract][Full Text] [Related]
9. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
Goedkoop AY; de Rie MA; Picavet DI; Kraan MC; Dinant HJ; van Kuijk AW; Tak PP; Bos JD; Teunissen MB
Arch Dermatol Res; 2004 Apr; 295(11):465-73. PubMed ID: 14968366
[TBL] [Abstract][Full Text] [Related]
10. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
[TBL] [Abstract][Full Text] [Related]
11. Treatment of palmoplantar psoriasis with intramuscular alefacept.
Myers W; Christiansen L; Gottlieb AB
J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
[TBL] [Abstract][Full Text] [Related]
12. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
Stenger EO; Chiang KY; Haight A; Qayed M; Kean L; Horan J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1845-52. PubMed ID: 26095669
[TBL] [Abstract][Full Text] [Related]
13. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late.
Vissers WH; Arndtz CH; Muys L; Van Erp PE; de Jong EM; van de Kerkhof PC
Br J Dermatol; 2004 May; 150(5):852-9. PubMed ID: 15149496
[TBL] [Abstract][Full Text] [Related]
14. Possibilities of using alefacept in the treatment of psoriasis.
Pietrzak A; Chodorowska G; Bartkowiak-Emeryk M; Pietrzak B; Urban J; Juszkiewicz-Borowiec M; Miturska R
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):311-3. PubMed ID: 15323211
[TBL] [Abstract][Full Text] [Related]
15. Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study.
Bovenschen HJ; Langewouters AM; van de Kerkhof PC
Am J Clin Dermatol; 2010; 11(5):343-50. PubMed ID: 20553063
[TBL] [Abstract][Full Text] [Related]
16. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases.
Thaçi D; Pätzold S; Kaufmann R; Boehncke WH
Br J Dermatol; 2005 May; 152(5):1048-50. PubMed ID: 15888169
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
Ortonne JP
J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
[TBL] [Abstract][Full Text] [Related]
18. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
[TBL] [Abstract][Full Text] [Related]
19. Targeting T-cell subsets to achieve remission.
Christophers E
J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():6-11. PubMed ID: 12795769
[TBL] [Abstract][Full Text] [Related]
20. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression.
Vissers WH; van Vlijmen I; van Erp PE; de Jong EM; van de Kerkhof PC
Br J Dermatol; 2008 Apr; 158(4):705-12. PubMed ID: 18284400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
